These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19712847)

  • 1. Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in HIV-infected patients after HAART (Highly Active Antiretroviral Therapy).
    Abellán-Martínez J; Guerra-Vales JM; Fernández-Cotarelo MJ; González-Alegre MT
    Eur J Intern Med; 2009 Sep; 20(5):474-7. PubMed ID: 19712847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
    Macías J; Melguizo I; Fernández-Rivera FJ; García-García A; Mira JA; Ramos AJ; Rivera JM; Pineda JA
    Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):775-81. PubMed ID: 12461586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fever of unknown origin in patients with HIV infection].
    Riera M; Altés J; Homar F; Picco G; Salas A; Leyes M; Cifuentes C; Artigues A; Villalonga C
    Enferm Infecc Microbiol Clin; 1996 Dec; 14(10):581-5. PubMed ID: 9052998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit.
    Palacios R; Hidalgo A; Reina C; de la Torre M; Márquez M; Santos J
    HIV Med; 2006 Apr; 7(3):193-6. PubMed ID: 16494634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fever of unknown origin in patients with human immunodeficiency virus infection. Study of 100 cases].
    Knobel H; Supevía A; Salvadó M; Gimeno JL; López-Colomes JL; Saballs P; Drobnic L; Díez A
    Rev Clin Esp; 1996 Jun; 196(6):349-53. PubMed ID: 8767068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.